← ANALYST RATINGS · TIPRANKS
Recursion Pharmaceuticals (RXRX): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy3 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $6.63, the highest $8.00, the lowest $5.90. The average is +91.4% from the last price of $3.46.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $4.50+12.5% | Hold | +29.9% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $4.50+12.5% | Hold | +29.9% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $4.50+12.5% | Hold | +29.9% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $4.00+14.3% | Hold | +15.4% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $4.50+12.5% | Hold | +29.9% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $4.50+28.6% | Hold | +29.9% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $5.30 → $5.90+11.3% | Hold | +70.3% | Assigned | 16.10.26on TipRanks 08:40 | −15.6% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $7.00 → $6.00−14.3% | Hold | +73.2% | Reiterated | 16.10.26on TipRanks 07:00 | −15.6% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | — | Buy | — | Reiterated | 15.09.26on TipRanks 13:30 | −4.5%next day −1.1% · 5 days +22.6% | ↗ |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | — | Hold | — | Reiterated | 05.08.26on TipRanks Aug 6 05:55 | −4.0%next day +0.5% · 5 days +3.4% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $8.00 | Buy | +130.9% | Reiterated | 05.08.26on TipRanks 15:06 | −4.0%next day +0.5% · 5 days +3.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Recursion Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.65 at a price of $4.13 (+61.0%); now: $6.63 at $3.46 (+91.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 5 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.22 (from $-0.25 to $-0.16). Last quarter: $-0.25.
Sales
Next quarter’s sales estimate — $15M (from $8M to $30M). Last quarter: $8M.
Best top-analyst consensus in the sector · Healthcare
About Recursion Pharmaceuticals
- CEO: Najat Khan
- Employees: 600
- 41 South Rio Grande Street, Salt Lake City, UT, 84101, US
- www.recursion.com
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Data from the stock’s TipRanks forecast page, read 64 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗